Condition
Cancer of the Liver
Total Trials
6
Recruiting
0
Active
0
Completed
1
Success Rate
16.7%-70% vs avg
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
83.3%
5 terminated out of 6 trials
Success Rate
16.7%
-69.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
300%
3 of 1 completed with results
Key Signals
3 with results
Data Visualizations
Phase Distribution
5Total
Not Applicable (2)
P 1 (2)
P 2 (1)
Trial Status
Terminated5
Completed1
Trial Success Rate
16.7%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT04107766TerminatedPrimary
NOLA (NeuWave Observational Liver Ablation) Registry
NCT00422877Phase 2TerminatedPrimary
Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract
NCT03753789Not ApplicableTerminatedPrimary
Ablation Confirmation Study
NCT01099631Phase 1CompletedPrimary
IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread
NCT02618447Not ApplicableTerminated
4D Phase Contrast MR: Hypertrophy in Liver Cancer
NCT00669136Phase 1Terminated
Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma
Showing all 6 trials